- Conditions: Overactive Bladder; Overactive Urinary Bladder
Interventions: Drug: MK-4618; Drug: Tolterodine ER; Drug: MK-1468 and Tolterodine ER; Other: Placebo (MK-4618); Other: Placebo (Tolterodine ER); Drug: Prophylactic Antibiotic
Sponsors: Merck; Merck
Recruiting - verified February 2012 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Closed loop with pramlintide; Device: Closed loop without pramlintide; Drug: Open loop with pramlintide
Sponsors: University of Virginia; University of Virginia; The Paul Manning Foundation (private)
Recruiting - verified September 2011 - Conditions: Obesity; Phentermine Withdrawal
Intervention: Drug: Abrupt cessation of phentermine pharmacotherapy
Sponsors: Center for Weight Management, California; Center for Weight Management, California; American Society of Bariatric Physicians
Recruiting - verified August 2011 - Condition: Chronic Rhinitis
Interventions: Drug: Placebo; Drug: Guaifenesin
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; Pfizer
Recruiting - verified May 2011 - Condition: Urinary Bladder, Overactive
Interventions: Drug: MK-4618 low-dose; Drug: MK-4618 mid-low dose; Drug: MK-4618 mid-high dose; Drug: tolterodine ER; Drug: Placebo for MK-4618; Drug: Placebo for tolterodine ER; Drug: MK-4618 high dose
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Overactive Bladder
Interventions: Drug: Tolterodine ER; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Type 1 Diabetes
Interventions: Drug: Pramlintide; Drug: Exenatide; Drug: Insulin
Sponsors: Albert Einstein College of Medicine of Yeshiva University; Albert Einstein College of Medicine of Yeshiva University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2012 - Condition: Chronic Oral Food Refusal
Interventions: Drug: Amitriptyline 1 mg/kg; Drug: Placebo
Sponsors: University of Kansas; Ann Davis, PhD, MPH, ABPP
Recruiting - verified March 2012 - Condition: Lower Urinary Tract Symptoms
Interventions: Drug: dutasteride 0.5 mg, used with tolterodine ER 4mg or placebo; Drug: dutasteride
Sponsors: Siami, Paul F., M.D.; Siami, Paul F., M.D.; GlaxoSmithKline; Pfizer
Recruiting - verified July 2011 - Conditions: Obesity; Binge Eating
Interventions: Behavioral: Behavioral Weight Loss; Behavioral: Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy; Drug: Placebo; Drug: Sibutramine
Sponsors: Yale University; Yale University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2012 - Conditions: Obesity; Binge Eating
Interventions: Drug: Sibutramine; Drug: Placebo; Behavioral: Self-help CBT + Sibutramine; Behavioral: Self-help CBT + Placebo
Sponsors: Yale University; Yale University; National Institutes of Health (NIH); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012
 |
Appetite Depressants Clinical Trials |
